AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $268,785 | -12.3% | 10,860 | +0.4% | 0.00% | 0.0% |
| Q2 2023 | $306,451 | +30.1% | 10,821 | +5.5% | 0.00% | 0.0% |
| Q1 2023 | $235,580 | -27.5% | 10,256 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $324,773 | +8.3% | 11,566 | +8.8% | 0.00% | 0.0% |
| Q3 2022 | $300,000 | +19.5% | 10,629 | -6.0% | 0.00% | 0.0% |
| Q2 2022 | $251,000 | -49.5% | 11,306 | -33.8% | 0.00% | 0.0% |
| Q1 2022 | $497,000 | -27.7% | 17,076 | -18.2% | 0.00% | 0.0% |
| Q4 2021 | $687,000 | -30.9% | 20,882 | -3.1% | 0.00% | -66.7% |
| Q3 2021 | $994,000 | -37.6% | 21,546 | -25.4% | 0.00% | -40.0% |
| Q2 2021 | $1,592,000 | +187.9% | 28,894 | +169.6% | 0.01% | +150.0% |
| Q1 2021 | $553,000 | +8.9% | 10,717 | -8.6% | 0.00% | 0.0% |
| Q4 2020 | $508,000 | +19.5% | 11,721 | -3.4% | 0.00% | 0.0% |
| Q3 2020 | $425,000 | -33.7% | 12,129 | +1.2% | 0.00% | -33.3% |
| Q2 2020 | $641,000 | +72.3% | 11,985 | +14.2% | 0.00% | 0.0% |
| Q1 2020 | $372,000 | -51.9% | 10,492 | -35.3% | 0.00% | -25.0% |
| Q4 2019 | $774,000 | +39.5% | 16,209 | -5.3% | 0.00% | +33.3% |
| Q3 2019 | $555,000 | -39.5% | 17,119 | -6.8% | 0.00% | -40.0% |
| Q2 2019 | $917,000 | -37.8% | 18,377 | -16.0% | 0.01% | -44.4% |
| Q1 2019 | $1,475,000 | +50.8% | 21,873 | +3.1% | 0.01% | +28.6% |
| Q4 2018 | $978,000 | -50.1% | 21,207 | -16.6% | 0.01% | -46.2% |
| Q3 2018 | $1,961,000 | -8.3% | 25,430 | +0.2% | 0.01% | -7.1% |
| Q2 2018 | $2,138,000 | -5.7% | 25,386 | -8.5% | 0.01% | -6.7% |
| Q1 2018 | $2,268,000 | +44.8% | 27,734 | +1.3% | 0.02% | +36.4% |
| Q4 2017 | $1,566,000 | -16.9% | 27,384 | -3.0% | 0.01% | -35.3% |
| Q3 2017 | $1,885,000 | +43.0% | 28,244 | +10.2% | 0.02% | +30.8% |
| Q2 2017 | $1,318,000 | -2.9% | 25,623 | +10.2% | 0.01% | -7.1% |
| Q1 2017 | $1,357,000 | +15.2% | 23,243 | -17.7% | 0.01% | +7.7% |
| Q4 2016 | $1,178,000 | -10.8% | 28,226 | +13.0% | 0.01% | -27.8% |
| Q3 2016 | $1,320,000 | +8.2% | 24,985 | -14.2% | 0.02% | +12.5% |
| Q2 2016 | $1,220,000 | +5.1% | 29,110 | +1.8% | 0.02% | 0.0% |
| Q1 2016 | $1,161,000 | -42.8% | 28,585 | -8.6% | 0.02% | -36.0% |
| Q4 2015 | $2,029,000 | -2.6% | 31,258 | +5.9% | 0.02% | -13.8% |
| Q3 2015 | $2,084,000 | -37.1% | 29,518 | -1.0% | 0.03% | -37.0% |
| Q2 2015 | $3,312,000 | +7.0% | 29,802 | -9.2% | 0.05% | +27.8% |
| Q1 2015 | $3,094,000 | +5.7% | 32,812 | +25.7% | 0.04% | +5.9% |
| Q4 2014 | $2,926,000 | +106.1% | 26,113 | +12.8% | 0.03% | +78.9% |
| Q3 2014 | $1,420,000 | +13.8% | 23,140 | -15.0% | 0.02% | +18.8% |
| Q2 2014 | $1,248,000 | +3.6% | 27,228 | -11.5% | 0.02% | +6.7% |
| Q1 2014 | $1,205,000 | +255.5% | 30,775 | +117.2% | 0.02% | +200.0% |
| Q4 2013 | $339,000 | – | 14,172 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |